Skip to content

Heart function in women with preeclampsia after treatment

Cardiac function in women with preeclampsia after treatment interventions

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12612000661875
Enrollment
40
Registered
2012-06-20
Start date
2011-11-17
Completion date
2018-09-27
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to determine heart function in pregnant women after they are treated for the disease of preeclampsia. The reason to do this is that the drug treatments that are used to control the high blood pressure in this disease have not been examined with respect to how they alter heart function in these sick pregnant women.

Interventions

Observations of cardiac function using transthoracic echocardiography at the time of treatment interventions. Transthoracic echocardiography will be performed prior to and after treatment interventions and also after the intervention of passive leg raising to assess stroke volume changes. Transthoracic echocardiography will also be performed in healthy pregnant women at rest and during passive leg raising. Transthoracic echocardiography examination will take approximately 15 minutes. The post-in

Observations of cardiac function using transthoracic echocardiography at the time of treatment interventions. Transthoracic echocardiography will be performed prior to and after treatment interventions and also after the intervention of passive leg raising to assess stroke volume changes. Transthoracic echocardiography will also be performed in healthy pregnant women at rest and during passive leg raising. Transthoracic echocardiography examination will take approximately 15 minutes. The post-intervention measurements will occur within 60 minutes of the drug being administered.

Sponsors

The Royal Women's Hosptial
Lead SponsorHospital

Eligibility

Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No

Inclusion criteria

Women with preeclampsia - non-labouring women, non-smokers, no vasoactive treatments or intravenous fluids adninstered, no previous cardiac disease or uterine abnormality. Healthy pregnant women - non-labouring women, no significant medical or surgical illness, non smokers, no uterine abnormalities and normally defined placentation. They will not be receiving any vasoactive medication including salbutamol or thyroid replacement hormones.

Exclusion criteria

labouring women, current administration of vasoactive drugs including salbutamol and thyroxine, pre-existing or gestational diabetes, smoking, and a known uterine abnormality.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026